The role of Iloprost on bone edema and osteonecrosis: Safety and clinical results

References

• Jäger M, Zilkens C, Bittersohl B, et al. Efficiency of iloprost treatment for osseous malperfusion. Int Orthop. 2011;35:761–765.
   PubMed Web of Science ®Google Scholar
• Elder GJ. From marrow oedema to osteonecrosis: common paths in the development of post-transplant bone pain. Nephrology (Carlton). 2006;11:560–567.
   PubMed Web of Science ®Google Scholar
• Beckmann J, Schmidt T, Schaumburger J, et al. Infusion, core decompression, or infusion following core decompression in the treatment of boneedema syndrome and early avascular osteonecrosis of the femoral head. Rheumatol Int. 2013;33:1561–1565.
   PubMed Web of Science ®Google Scholar
• Curtiss PH Jr, Kincaid WE. Transitory demineralization of the hip in pregnancy: a report of three cases. J Bone Joint Surg [Am]. 1959;41-A:1327–1333.
   PubMed Web of Science ®Google Scholar
• Wilson AJ, Murphy WA, Hardy DC, et al. Transient osteoporosis: transient bone marrow edema? Radiology. 1988;167:757–760.
   PubMed Web of Science ®Google Scholar
• Asadipooya K, Graves L, Greene LW. Transient osteoporosis of the hip: review of the literature. Osteoporos Int. 2017;28:1805–1816.
   PubMed Web of Science ®Google Scholar
• Lakhanpal S, Ginsburg WW, Luthra HS, et al. Transient regional osteoporosis. A study of 56 cases and review of the literature. Ann Intern Med. 1987;106:444–450.
   PubMed Web of Science ®Google Scholar
• Mirghasemi SA, Trepman E, Sadeghi MS, et al. Bone marrow edema syndrome in the foot and ankle. Foot Ankle Int. 2016;37:1364–1373.
   PubMed Web of Science ®Google Scholar
• Korompilias AV, Karantanas AH, Lykissas MG, et al. Bone marrow edema syndrome. Skeletal Radiol. 2009;38:425–436.
   PubMed Web of Science ®Google Scholar
• Solomon L. Bone-marrow oedema syndrome. J Bone Joint Surg Br. 1993;75:175–176.
   PubMedGoogle Scholar
• Hofmann S, Kramer J, Vakil-Adli A, et al. Painful bone marrow edema of the knee: differential diagnosis and therapeutic concepts. Orthop Clin North Am. 2004;35:321–333.
   PubMed Web of Science ®Google Scholar
• Anagnostakos K, Orth P. Role of serum lipoprotein at the site of iloprost therapy in the treatment of painful bone marrow edema. Orthopedics. 2013;36:e1283–9.
   PubMed Web of Science ®Google Scholar
• Orth P, Anagnostakos K. Coagulation abnormalities in osteonecrosis and bone marrow edema syndrome. Orthopedics. 2013;36:290–300.
   PubMed Web of Science ®Google Scholar
• Simon MJ, Barvencik F, Luttke M, et al. Intravenous bisphosphonates and vitamin D in the treatment of bone marrow oedema in professional athletes. Injury. 2014;45:981–987.
   PubMed Web of Science ®Google Scholar
• Rozenbaum M, Zinman C, Nagler A, et al. Transient osteoporosis of hip joint with liver cirrhosis. J Rheumatol. 1984;11:241–243.
   PubMed Web of Science ®Google Scholar
• Lavernia CJ, Sierra RJ, Grieco FR. Osteonecrosis of the femoral head. J Am Acad Orthop Surg. 1999;7:250–261.
   PubMedGoogle Scholar
• Vail TP, Covington DB. The incidence of osteonecrosis. In: Urbaniak JR, Jones JR, editors. Osteonecrosis: etiology, diagnosis, treatment. Rosemont, IL: American Academy of Orthopedic Surgeons; 1997. p. 43–49.
   Google Scholar
• Tsuji T, Sugano N, Sakai T, et al. Evaluation of femoral perfusion in a non-traumatic rabbit osteonecrosis model with T2*-weighted dynamic MRI. J Orthop Res. 2003;21:341–351.
   PubMed Web of Science ®Google Scholar
• Uchio Y, Ochi M, Adachi N, et al. Intraosseous hypertension and venous congestion in osteonecrosis of the knee. Clin Orthop Relat Res. 2001;384:217–223.
   Google Scholar
• Arlet J, Ficat P, Sebbag D. The use of measurement of intramedullary pressure in the greater trochanter in man, particularly in the diagnosis of osteonecrosis of the femoral head. Rev Rhum Mal Osteoartic. 1968;35:250–256.
   PubMedGoogle Scholar
• Guerado E, Caso E. The physiopathology of avascular necrosis of the femoral head: an update. Injury. 2016 Dec;47(Suppl 6):S16–S26.
   PubMedGoogle Scholar
• Phemister DB. Repair of bone in the presence of aseptic necrosis resulting from fracture transplantation and vascular disorders. J Bone Jt Surg. 1930;12:769–787.
   Google Scholar
• Catto MA. Histological study of avascular necrosis of the femoral head after transcervical fracture. J Bone Jt Surg Br. 1965;47:749–776.
   PubMedGoogle Scholar
• Catto M. Pathology of aseptic bone necrosis. In: Davidson JK, editor. Aseptic necrosis of bone. 1st ed. Amsterdam, Nederlands: Excerp- ta Medica;1976:3-100.
   Google Scholar
• Ficat RP, Arlet J. Necrosis of the femoral head. In: Hungerford DS, editor. Ischemia and necrosis of bone. Baltimore, MD: Williams & Wilkins; 1980. p. 171–182.
   Google Scholar
• Luo RB, Lin T, Zhong HM, et al. Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review. Med Sci Monit. 2014;20:2439–2447.
   PubMed Web of Science ®Google Scholar
• Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001;386:173–178.
   Google Scholar
• Gao F, Sun W, Li Z, et al. High-energy extracorporeal shock wave for early stage osteonecrosis of the femoral head: a single-center case series. Evid Based Complement Alternat Med. 2015;2015:468090.
   PubMedGoogle Scholar
• Laroche M, Jacquemier JM, Montane de la Rouge P, et al. La Nifedipine per Os Ameliore Les Douleurs De L’osteonecrose De La Tete Femorale. Rev Rhumat. 1990;57:669–670.
   PubMedGoogle Scholar
• Glueck CJ, Freiberg R, Glueck HI, et al. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol. 1995;48:213–220.
   PubMed Web of Science ®Google Scholar
• Hernigou P, Trousselier M, Roubineau F, et al. Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress. Clin Orthop Surg. 2016;81:1–8.
   Google Scholar
• Cheung KW, Chiu KH, Chung KY. Long-term result of cementless femoral stem in avascular necrosis of the hip. Hip Int. 2015;251:72–75.
   Google Scholar
• Pountos I, Georgouli T, Bird H, et al. The effect of antibiotics on bone healing: current evidence. Expert Opin Drug Saf. 2011;10:935–945.
   PubMed Web of Science ®Google Scholar
• Pountos I, Georgouli T, Calori GM, et al. Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. Scientific World J. 2012;2012:606404.
   Google Scholar
• Pountos I, Georgouli T, Bird H, et al. Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects. Int J Interferon, Cytokine Mediator Res. 2011;3:19–27.
   Google Scholar
• Stock G, Müller B, Krais T, et al. Iloprost, a stable analogue of PGI2: clinical results and pathophysiological considerations. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:583–589.
   PubMedGoogle Scholar
• Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs. 1992;43:889–924.
   PubMed Web of Science ®Google Scholar
• Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res. 2004;94:1101–1108.
   PubMed Web of Science ®Google Scholar
• Kassis HM, Minsinger KD, McCullough PA, et al. Review of the use of iloprost, a synthetic prostacyclin, in the prevention of radio contrast nephropathy in patients undergoing coronary angiography and intervention. Clin Cardiol. 2015;38:492–498.
   PubMed Web of Science ®Google Scholar
• Coppolino G, Buemi A, Bolignano D, et al. Perioperative iloprost and endothelial progenitor cells in uremic patients with severe limb ischemia undergoing peripheral revascularization. J Surg Res. 2009;157:e129–35.
   PubMed Web of Science ®Google Scholar
• Kawald A, Burmester GR, Huscher D, et al. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud’s phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol. 2008;35:1830–1837.
   PubMed Web of Science ®Google Scholar
• Linnemann B, Erbe M. Raynaud’s phenomenon and digital ischaemia–pharmacologic approach and alternative treatment options. Vasa. 2016;45:201–212.
   PubMed Web of Science ®Google Scholar
• Okiji T, Morita I, Kawashima N, et al. Immunohistochemical detection of prostaglandin I2 synthase in various calcified tissue-forming cells in rat. Arch Oral Biol. 1993;38:31–36.
   PubMed Web of Science ®Google Scholar
• Partridge NC, Kemp BE, Livesey SA, et al. Activity ratio measurements reflect intracellular activation of adenosine 3ʹ,5ʹ-monophosphate-dependent protein kinase in osteoblasts. Endocrinology. 1982;111:178–183.
   PubMed Web of Science ®Google Scholar
• Khanin M, Liel Y, Rimon G. Differential effect of TPA on PGE2 and cicaprost-induced cAMP synthesis in UMR-106 cells. Cell Signal. 1999;11:165–169.
   PubMed Web of Science ®Google Scholar
• Sarrazin P, Bkaily G, Haché R, et al. Characterization of the prostaglandin receptors in human osteoblasts in culture. Prostaglandins Leukot Essent Fatty Acids. 2001;64:203–210.
   PubMed Web of Science ®Google Scholar
• Robin JC, Brown MJ, Weinfeld N, et al. Prostacyclin: effects on cyclic AMP in bone cells. Res Commun Chem Pathol Pharmacol. 1982;35:43–49.
   PubMedGoogle Scholar
• Wang J, Yamamoto K, Sugimoto Y, et al. Induction of prostaglandin I(2) receptor by tumor necrosis factor alpha in osteoblastic MC3T3-E1 cells. Biochim Biophys Acta. 1999;1441:69–76.
   PubMed Web of Science ®Google Scholar
• Glantschnig H, Varga F, Rumpler M, et al. Prostacyclin (PGI2): a potential mediator of c-fos expression induced by hydrostatic pressure in osteoblastic cells. Eur J Clin Invest. 1996;26:544–548.
   PubMed Web of Science ®Google Scholar
• Jearanaiphaisarn T, Sanharati T, Pavasant P, et al. The effect of iloprost on cell proliferation and angiogenesis-related gene expression in human periodontal ligament cells. Odontology. 2017
   PubMed Web of Science ®Google Scholar
• Kemper O, Herten M, Fischer J, et al. Prostacyclin suppresses twist expression in the presence of indomethacin in bone marrow-derived mesenchymal stromal cells. Med Sci Monit. 2014;20:2219–2227.
   PubMed Web of Science ®Google Scholar
• Doğan A, Duygun F, Kalender AM, et al. Iloprost inhibits fracture repair in rats. Chin Med J (Engl). 2014;127:2960–2965.
   PubMed Web of Science ®Google Scholar
• Nakalekha C, Yokoyama C, Miura H, et al. Increased bone mass in adult prostacyclin-deficient mice. J Endocrinol. 2010;204:125–133.
   PubMed Web of Science ®Google Scholar
• Deng Y, Yang Z, Terry T, et al. Prostacyclin-producing human mesenchymal cells target H19 lncRNA to augment endogenous progenitor function in hindlimb ischaemia. Nat Commun. 2016;7:11276.
   PubMed Web of Science ®Google Scholar
• Aigner N, Petje G, Steinboeck G, et al. Treatment of bone-marrow oedema of the talus with the prostacyclin analogue iloprost. An MRI-controlled investigation of a new method. J Bone Joint Surg Br. 2001;83:855–858.
   PubMedGoogle Scholar
• Jäger M, Tillmann FP, Thornhill TS, et al. Rationale for prostaglandin I2 in bone marrow oedema–from theory to application. Arthritis Res Ther. 2008;10:R120.
   PubMed Web of Science ®Google Scholar
• Claßen T, Becker A, Landgraeber S, et al. Long-term clinical results after iloprost treatment for bone marrow edema and avascular necrosis. Orthop Rev (Pavia). 2016;8:6150.
   PubMed Web of Science ®Google Scholar
• Meizer R, Meraner D, Meizer E, et al. Outcome of painful bone marrow edema of the femoral head following treatment with parenteral iloprost. Indian J Orthop. 2009;43:36–39.
   PubMed Web of Science ®Google Scholar
• Jäger M, Zilkens C, Westhoff B, et al. Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childhood cancer. Anticancer Res. 2009;29:3433–3440.
   PubMed Web of Science ®Google Scholar
• Röhner E, Zippelius T, Steindl D, et al. Effects of intravenous iloprost therapy in patients with bone marrow oedema of the foot and ankle. Eur J Orthop Surg Traumatol. 2014;24:1609–1616.
   PubMedGoogle Scholar
• Aigner N, Petje G, Schneider W, et al. Bone marrow edema syndrome of the femoral head: treatment with the prostacyclin analogue iloprost vs. core decompression: an MRI-controlled study. Wien Klin Wochenschr. 2005 Feb;117(4):130–135.
   PubMed Web of Science ®Google Scholar
• Mayerhoefer ME, Kramer J, Breitenseher MJ, et al. Short-term outcome of painful bone marrow oedema of the knee following oral treatment with iloprost or tramadol: results of an exploratory phase II study of 41 patients. Rheumatology (Oxford). 2007;46:1460–1465.
   PubMed Web of Science ®Google Scholar
• Baier C, Schaumburger J, Götz J, et al. Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot. Rheumatol Int. 2013;33:1397–1402.
   PubMed Web of Science ®Google Scholar
• Meini S, Panigada G. Proposal of early retreatment with iloprost in partially responsive patients with bone marrow edema syndrome: a case report. Italian J Med. 2012;6:332–337.
   Google Scholar
• Disch AC, Matziolis G, Perka C. The management of necrosis-associated and idiopathic bone-marrow oedema of the proximal femur by intravenous iloprost. J Bone Joint Surg Br. 2005;87:560–564.
   PubMedGoogle Scholar
• Meizer R, Radda C, Stolz G, et al. MRI-controlled analysis of 104 patients with painful bone marrow edema in different joint localizations treated with the prostacyclin analogue iloprost. Wien Klin Wochenschr. 2005;117:278–286.
   PubMed Web of Science ®Google Scholar
• Aigner N, Radda C, Meizer R, et al. Bone marrow edema in the foot—MRI findings after conservative therapy. Foot Ankle Surg. 2005;11:87–91.
   Google Scholar
• Aigner N, Meizer R, Stolz G, et al. Iloprost for the treatment of bone marrow edema in the hindfoot. Foot Ankle Clin. 2003;8:683–693.
   PubMedGoogle Scholar
• Mayerhoefer ME, Kramer J, Breitenseher MJ, et al. MRI-demonstrated outcome of subchondral stress fractures of the knee after treatment with iloprost or tramadol: observations in 14 patients. Clin J Sport Med. 2008;18:358–362.
   PubMed Web of Science ®Google Scholar
• Aigner N, Petje G, Steinboeck G, et al. Bone marrow edema of the forefoot after chevron osteotomy–a rare cause of metatarsalgia: a case report. Foot Ankle Int. 2002;23:447–451.
   PubMed Web of Science ®Google Scholar
• Aigner N, Petje G, Schneider W, et al. Juvenile bone-marrow oedema of the acetabulum treated by iloprost. J Bone Joint Surg Br. 2002;84:1050–1052.
   PubMedGoogle Scholar
• Arazi M, Yel M, Uguz B, et al. Be aware of bone marrow edema syndrome in ankle arthroscopy: a case successfully treated with iloprost. Arthroscopy. 2006;22:909.e1-3.
   PubMed Web of Science ®Google Scholar
• Disch AC, Matziolis G, Reinke P, et al. Intravenous Iloprost treatment for severe bone pain caused by sickle cell crisis. Thromb Haemost. 2004;91:1047–1049.
   PubMed Web of Science ®Google Scholar
• Lackner H, Benesch M, Moser A, et al. Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study. J Pediatr Hematol Oncol. 2005;27:259–263.
   PubMed Web of Science ®Google Scholar
• Arazi M, Kiresi D. Bone marrow edema syndrome of the third metatarsal bone: a rare cause of metatarsalgia treated with Iloprost. Eur J Orthopaedic Surg Traumatol. 2011;21:59–62.
   Google Scholar
• Aigner N, Meizer R, Meraner D, et al. Bone marrow edema syndrome in postpartal women: treatment with iloprost. Orthop Clin North Am. 2009;40:241–247.
   PubMed Web of Science ®Google Scholar
• Tunçbilek G, Korkusuz P, Ozgür F. Effects of iloprost on calvarial sutures. J Craniofac Surg. 2008;19:1472–1480.
   PubMed Web of Science ®Google Scholar
• Koo KH, Ahn IO, Kim R, et al. Bone marrow edema and associated pain in early stage osteonecrosis of the femoral head: prospective study with serial MR images. Radiology. 1999;213:715–722.
   PubMed Web of Science ®Google Scholar
• Koo KH, Jeong ST, Jones JP Jr. Borderline necrosis of the femoral head. Clin Orthop Relat Res. 1999;358:158–165.
   Google Scholar
• Hofmann S, Kramer J, Leder K, et al. The non-traumatic femur head necrosis in the adult. I: pathophysiology, clinical picture and therapeutic options. Radiologe. 1994;34:1–10.
   PubMedGoogle Scholar
• Guerra JJ, Steinberg ME. Distinguishing transient osteoporosis from avascular necrosis of the hip. J Bone Joint Surg Am. 1995;77:616–624.
   PubMed Web of Science ®Google Scholar
• Hungerford DS. Role of core decompression as treatment method for ischemic femur head necrosis. Orthopade. 1990;19:219–223.
   PubMed Web of Science ®Google Scholar
• Nemoto K, Pilbeam CC, Bilak SR, et al. Molecular cloning and expression of a rat prostaglandin E2 receptor of the EP2 subtype. Prostaglandins. 1997;54:713–725.
   PubMed Web of Science ®Google Scholar
• Kasugai S, Oida S, Iimura T, et al. Expression of prostaglandin E receptor subtypes in bone: expression of EP2 in bone development. Bone. 1995;17:1–4.
   PubMed Web of Science ®Google Scholar
• Ciabattoni G, Tamburrelli F, Greco F. Increased prostacyclin biosynthesis in patients with osteoid osteoma. Eicosanoids. 1991;4: 165–167. Meizer Meizer.
   PubMedGoogle Scholar
• Pilge H, Bittersohl B, Schneppendahl J, et al. Bone marrow aspirate concentrate in combination with intravenous iloprost increases bone healing in patients with avascular necrosis of the femoral head: a matched pair analysis. Orthop Rev (Pavia). 2017;8:6902.
   PubMed Web of Science ®Google Scholar